U.S. Monkeypox Vaccine And Treatment Market Size & Outlook
Related Markets
U.S. monkeypox vaccine and treatment market highlights
- The U.S. monkeypox vaccine and treatment market generated a revenue of USD 86,496.9 million in 2024 and is expected to reach USD 65,853.7 million by 2030.
- The U.S. market is expected to grow at a CAGR of -4.4% from 2025 to 2030.
- In terms of segment, drugs was the largest revenue generating product in 2024.
- Vaccine is the most lucrative product segment registering the fastest growth during the forecast period.
Monkeypox vaccine and treatment market data book summary
| Market revenue in 2024 | USD 86,496.9 million |
| Market revenue in 2030 | USD 65,853.7 million |
| Growth rate | -4.4% (CAGR from 2025 to 2030) |
| Largest segment | Drugs |
| Fastest growing segment | Vaccine |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Drugs, Vaccine, Vaccinia Immune Globulin (VIG) |
| Key market players worldwide | Bavarian Nordic A/S, SIGA Technologies Inc, Chimerix Inc, Emergent BioSolutions Inc, Gilead Sciences Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 39.8% of the global monkeypox vaccine and treatment market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. monkeypox vaccine and treatment market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 6,720.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Monkeypox Vaccine And Treatment Market Scope
Monkeypox Vaccine And Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Chimerix Inc | View profile | 72 | 2505 Meridian Parkway, Suite 100, Durham, NC, United States, 27713 | https://www.chimerix.com |
| Bavarian Nordic A/S | View profile | 1381 | Philip Heymans Alle 3, Hellerup, Denmark, DK-2900 | https://www.bavarian-nordic.com |
| SIGA Technologies Inc | View profile | 45 | 31 East 62nd Street, New York, NY, United States, 10065 | https://www.siga.com |
| Emergent BioSolutions Inc | View profile | 1600 | 300 Professional Drive, Gaithersburg, MD, United States, 20879 | https://www.emergentbiosolutions.com |
| Gilead Sciences Inc | View profile | 18000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | https://www.gilead.com |
U.S. monkeypox vaccine and treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to monkeypox vaccine and treatment market will help companies and investors design strategic landscapes.
Drugs was the largest segment with a revenue share of 74.22% in 2024. Horizon Databook has segmented the U.S. monkeypox vaccine and treatment market based on drugs, vaccine, vaccinia immune globulin (vig) covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to U.S. monkeypox vaccine and treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. monkeypox vaccine and treatment market databook
-
Our clientele includes a mix of monkeypox vaccine and treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. monkeypox vaccine and treatment market , including forecasts for subscribers. This country databook contains high-level insights into U.S. monkeypox vaccine and treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. monkeypox vaccine treatment market report size, by product, 2018-2030 (US$M)
U.S. Monkeypox Vaccine And Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
